NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
OTC · CRVW · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
CareView Communications, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow CareView Communications, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
CareView Communications, Inc., established in 1997 and based in Lewisville, Texas, specializes in delivering advanced monitoring solutions to the U.S. healthcare industry. Its primary offering, the CareView Patient Safety System, is a video-based monitoring tool designed to elevate nursing standards, foster a more positive staff environment, and enhance the overall patient experience in diverse settings, including hospitals, nursing homes, adult living centers, and outpatient facilities. The company also provides the Caregiver Platform, which integrates the Caregiver Connect mobile application. This app offers a streamlined and user-friendly interface for managing essential caregiving workflows, such as acknowledging and documenting resident alert responses. For the long-term care sector, CareView offers CareView Connect, a comprehensive resident monitoring system. This solution features both wearable and stationary buttons that allow residents to summon assistance or signal emergencies, alongside a mobile application that transmits alerts to caregivers and enables them to record incident details. An integrated alert management and monitoring system underpins this service. Furthermore, CareView's SitterView and TeleMedView platforms leverage its video camera technology, empowering hospital personnel to remotely observe and communicate with patients.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:12 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$290.97+$4.98 (+1.74%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.55% below the high.
$410.91+$3.81 (+0.94%)
UnitedHealth Group Incorporated’s quoted price sits in the upper half of its reported 52-week range, 10.99% below the high.
$146.33+$5.40 (+3.83%)
Merck & Co., Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.75% below the high.
$4.19+$0.02 (+0.48%)
Owlet, Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.27% below the high.
$1.62-$0.15 (-8.48%)
Pulsenmore Ltd. Ordinary Shares’s quoted price sits in the lower half of its reported 52-week range, 87.51% below the high.
$0.06+$0.00 (+5.45%)
Biotricity, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.17% below the high.
